Weaver Consulting Group’s XBiotech XBIT Stock Holding History

Weaver Consulting Group’s Portfolio XBIT Stock Details XBIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-600	Closed	-$12K	–	917
2020 Q3	$12K	Buy	+600	New	+$10.4K	0.01%	529

Other funds holding XBIT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CCM

CAAS Capital Management New York $934M AUM 1.45% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Weaver Consulting Group's XBIT Position: Q4 2020 in Review

Weaver Consulting Group sold out of XBiotech (XBIT) in Q4 2020, closing a stake of 600 shares — an estimated $12K sold.

Weaver Consulting Group first reported a position in XBIT in Q3 2020 and held it in 1 quarter. The position peaked at $12K in Q3 2020. 66 funds tracked by Wall St. Rank hold XBIT as of Q4 2020.

Weaver Consulting Group reported no remaining XBiotech position as of Q4 2020 after selling out during the quarter.
Weaver Consulting Group sold 600 XBiotech shares in Q4 2020, an estimated $12K.
Weaver Consulting Group first reported a position in XBiotech in Q3 2020 and held it in 1 quarter.
Weaver Consulting Group's XBiotech position peaked at $12K in Q3 2020.
66 funds tracked by Wall St. Rank held XBiotech as of Q4 2020.

Based on Weaver Consulting Group's 13F filing for Q4 2020, filed 29 Jan 2021.